Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV000998437 | SCV001154514 | likely pathogenic | not provided | 2019-02-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001051306 | SCV001215452 | uncertain significance | Renal carnitine transport defect | 2022-07-19 | criteria provided, single submitter | clinical testing | This sequence change replaces tyrosine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 124 of the SLC22A5 protein (p.Tyr124Cys). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This missense change has been observed in individual(s) with clinical features of primary carnitine deficiency (PMID: 32371215). ClinVar contains an entry for this variant (Variation ID: 809800). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt SLC22A5 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Genome- |
RCV001051306 | SCV002055742 | uncertain significance | Renal carnitine transport defect | 2021-07-15 | criteria provided, single submitter | clinical testing | |
Giacomini Lab, |
RCV001051306 | SCV002576663 | uncertain significance | Renal carnitine transport defect | 2022-10-03 | criteria provided, single submitter | research | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003987757 | SCV004803266 | uncertain significance | not specified | 2024-01-12 | criteria provided, single submitter | clinical testing | Variant summary: SLC22A5 c.371A>G (p.Tyr124Cys) results in a non-conservative amino acid change located in the Major facilitator superfamily domain (IPR020846) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 8.3e-06 in 239790 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.371A>G has been reported in the literature in at least one compound heterozygous individual affected with Primary Carnitine Deficiency (e.g., Lin_2020). These data do not allow any conclusion about variant significance. At least one publication reports experimental evidence evaluating an impact on protein function, finding that the variant results in an approximately 80% reduction in carnitine transport function relative to the wild-type protein (e.g., Koleske_2022). The following publications have been ascertained in the context of this evaluation (PMID: 36343260, 32371215). ClinVar contains an entry for this variant (Variation ID: 809800). Based on the evidence outlined above, the variant was classified as VUS-possibly pathogenic. |
Natera, |
RCV002226506 | SCV002078301 | uncertain significance | Decreased circulating carnitine concentration | 2020-07-08 | no assertion criteria provided | clinical testing | |
Natera, |
RCV001051306 | SCV002107424 | uncertain significance | Renal carnitine transport defect | 2020-07-08 | no assertion criteria provided | clinical testing |